SEC Form 4 · accession 0001493152-26-043383

Vivos Therapeutics, Inc. · VVOS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jun 30, 2026

Accepted (ET)

Sep 18, 2026 · 5:04 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001716166

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Preferred Stock^F2	Jun 30, 2026	J	85,910	$0.582	A	85,910	I	See footnote
Common Stock	holding	—	—		—	3,461	D
Common Stock^F1	holding	—	—		—	69,600	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant (Right to Buy)^F2	$0.456	Jun 30, 2026	J	85,910	A	Jun 30, 2026	Jun 30, 2031	Common Stock	85,910	85,910	I
Stock Options (Right to Buy)^F3	—	holding	—	—	—	Sep 18, 2026	Feb 25, 2027	Common Stock	359,754	359,754	D

F1Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.
F2On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein.
F3Represents employee stock options granted on various dates, with exercise prices ranging from $2.38 to $81.75 and expiration dates ranging from February 25, 2027 to September 7, 2034, and also reflects the expiry of 5,001 stock options granted June 16, 2021 that were previously reported on the Reporting Person's Form 4 filed on November 27, 2024, which expired unexercised on June 26, 2026. Table II reports the earliest expiration dates (02/25/2027).